RT Journal Article
T1 Bone health and therapeutic agents in advanced prostate cancer.
A1 Gómez-Aparicio, Maria Antonia
A1 López-Campos, Fernando
A1 Pelari-Mici, Lira
A1 Buchser, David
A1 Pastor, Jorge
A1 Maldonado, Xavier
A1 Zafra, Juan
A1 Tree, Alison C
A1 Bultijnck, Renée
A1 Sargos, Paul
A1 Ost, Piet
A1 Couñago, Felipe
K1 Bisphosphonates
K1 Bone health
K1 Denosumab
K1 Osteoporosis
K1 Prostate cancer
K1 Skeletal-related events
AB Prostate cancer is the most frequent genitourinary tumor worldwide. Maintaining an optimum bone health throughout the natural course of prostate cancer is an important aspect in the management of this disease, particularly in this at risk population of older and frail patients who experience bone loss related to androgen-deprivation therapy (ADT) and/or patients who develop bone metastases. The number of treatment options for advanced prostate cancer that combine ADT with docetaxel, new hormonal agents and/or radiotherapy has increased substantially in recent years. Bisphosphonates and other bone targeted agents such as denosumab have shown an improvement in bone mineral density and are suited for patients with treatment-related osteoporosis and/or bone metastases with an increased risk of skeletal-related events (SREs). In this context, the aim of this review is to analyse key aspects of bone health and therapies that can prevent the occurrence of SREs throughout the clinical course of prostate cancer, and how to combine them with new available treatments in this setting.
YR 2022
FD 2022
LK http://hdl.handle.net/10668/21809
UL http://hdl.handle.net/10668/21809
LA en
DS RISalud
RD Apr 19, 2025